Drug Profile
Research programme: infectious disease therapeutics - Auritec/EyePoint Pharmaceuticals
Latest Information Update: 05 Apr 2018
Price :
$50
*
At a glance
- Originator pSivida
- Developer Auritec Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections; Viral infections
Most Recent Events
- 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
- 10 Oct 2012 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 10 Oct 2012 Discontinued - Preclinical for Viral infections in USA (unspecified route)